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Abstract
Background: Zinc deficiency is commonly prevalent in children in developing countries and plays a role in
decreased immunity and increased risk of infection. Preventive zinc supplementation in healthy children can
reduce mortality due to common causes like diarrhea, pneumonia and malaria. The main objective was to
determine all-cause mortality and cause-specific mortality and morbidity in children under five in developing
countries for preventive zinc supplementation.
Data sources/ review methods: A literature search was carried out on PubMed, the Cochrane Library and the
WHO regional databases to identify RCTs on zinc supplementation for greater than 3 months in children less than
5 years of age in developing countries and its effect on mortality was analyzed.
Results: The effect of preventive zinc supplementation on mortality was given in eight trials, while cause specific
mortality data was given in five of these eight trials. Zinc supplementation alone was associated with a statistically
insignificant 9% (RR = 0.91; 95% CI: 0.82, 1.01) reduction in all cause mortality in the intervention group as compared to
controls using a random effect model. The impact on diarrhea-specific mortality of zinc alone was a non-significant 18%
reduction (RR = 0.82; 95% CI: 0.64, 1.05) and 15% for pneumonia-specific mortality (RR = 0.85; 95% CI: 0.65, 1.11). The
incidence of diarrhea showed a 13% reduction with preventive zinc supplementation (RR = 0.87; 95% CI: 0.81, 0.94) and
a 19% reduction in pneumonia morbidity (RR = 0.81; 95% CI: 0.73, 0.90). Keeping in mind the direction of effect of zinc
supplementation in reducing diarrhea and pneumonia related morbidity and mortality; we considered all the outcomes
for selection of effectiveness estimate for inclusion in the LiST model. After application of the CHERG rules with
consideration to quality of evidence and rule # 6, we used the most conservative estimates as a surrogate for mortality.
We, therefore, conclude that zinc supplementation in children is associated with a reduction in diarrhea mortality of
13% and pneumonia mortality of 15% for inclusion in the LiST tool. Preventive zinc supplementation had no effect on
malaria specific mortality (RR = 0.90; 95% CI: 0.77, 1.06) or incidence of malaria (RR=0.92; 95 % CI 0.82-1.04)
Conclusion: Zinc supplementation results in reductions in diarrhea and pneumonia mortality.
Introduction
About 30% of the world’s population is zinc deficient
[1], most prevalent in children under 5 years of age in
developing countries [2]. Zinc deficiency is associated
with impaired immune function which results in an
increase in morbidity due to infections, growth
retardation, hypogonadism and cognitive dysfunction
[3,4]. Zinc deficiency is primarily related to the con-
sumed diet; zinc is most abundant and easily absorbable
from animal proteins, whereas consumption of vegetable
and cereals decreases its absorption due to binding of
zinc to phytates [5,6].
Over the past two decades, strong evidence has come
forward from multiple randomized controlled trials, in
both developed and developing countries, showing an
effect of zinc in decreasing morbidity and mortality in
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children due to gastrointestinal and respiratory infec-
tions [7,8]. More recent trials from sub-Saharan coun-
tries have also shown an effect on malarial morbidity
[9]. This effect of zinc against infectious diseases is ther-
apeutic as well as preventive. Previous reviews by the
Zinc Investigators’ Collaborative Group in 1999 [10] and
by Aggarwal et al. [11] have studied the effect of preven-
tive zinc supplementation on diarrheal and respiratory
morbidity. The current systematic review presents the
effect of zinc supplementation on mortality in children
less than 5 years of age in developing countries. The evi-
dence for the effect of zinc supplementation on cause-
specific mortality and morbidity is assessed for diarrhea,
pneumonia and malaria according to guidelines set by
the Child Health Epidemiology reference Group
(CHERG) for input into the Lives Saved Tool (LiST)
model [12].
Methods
Searching
A comprehensive literature search was conducted using
the following search strategy: zinc AND (infection OR
diarrhea OR pneumonia OR ARI OR malaria OR mor-
bidity OR mortality OR death) in electronic biblio-
graphic databases i.e. PubMed, the Cochrane Library
and WHO regional search engines, including articles
cited up to September 25th 2010 . The limits used were
“Humans” and “Randomized controlled trials”. Addi-
tional studies were obtained through hand search of
references from identified studies. One author reviewed
the titles and abstracts to identify controlled studies
conducted in developing countries in which supplemen-
tal zinc was administered and outcomes on mortality or
morbidity were reported. Two authors independently
assessed eligibility using the pre-defined inclusion and
exclusion criteria and performed the data extraction.
Any discrepancies between the reviewers in either the
decision of inclusion or exclusion of studies or in data
extraction were resolved by discussion aimed at reaching
consensus among all.
Selection (inclusion/exclusion criteria)
Individual- or cluster-randomized controlled trials of
routine (i.e. daily or weekly) zinc supplementation admi-
nistered to children less than 5 years of age in develop-
ing countries.
• Studies with zinc supplementation carried out for 3
months of intervention in both intervention and com-
parison groups.
• Trials in which other nutrient co-interventions [e.g.,
vitamin A, riboflavin, iron-folic acid (IFA)] were admi-
nistered to both control and zinc arms were included.
Results were analyzed with and without studies in which
zinc was given with IFA.
• Studies on small-for-gestational age or low birth
weight infants were excluded from the review.
Validity assessment
The quality assessment of each study was carried out on
key variables with regard to study design, study limita-
tions, intervention specifics, and outcome specific and
graded according to the adapted GRADE technique
[12,13]. Any study with a final grade of very low was
excluded from the review. This review is shaped in large
part by the needs of the LiST model. In this model,
increases in coverage of an intervention results in a
reduction of one or more cause-specific deaths or in
reduction of a risk factor. Therefore the reviews and the
grade process used were designed to develop estimates
of the effect of an intervention in reducing either a risk
factor or a death due to specific cause. For more details
of the review methods, the adapted grade approach or
the LiST model, see the method’s paper[12].
Data abstraction
Data from all studies that met final inclusion and exclu-
sion criteria were abstracted into a standardised form
for each outcome of interest [12]. Data extracted from
each eligible study included the following primary out-
come variables: total number of deaths in both arms,
deaths due to specific infection (diarrhea, pneumonia or
malaria), the total number of episodes of illness (diar-
rhea, pneumonia and malaria) in each arm, the total
amount of person-time accumulated in each arm
(reported as person-days) and incidence rate ratio (IRR).
Quantitative data synthesis
Meta-analyses were generated for all-cause mortality
and cause specific mortality of diarrhea, pneumonia and
malaria in children under 5 years of age. Pooled esti-
mates for incidence of diarrhea, respiratory disease and
malaria were also generated. Data from cluster rando-
mised trials were pooled with that of individual rando-
mised trial. In this case, cluster adjusted values were
used irrespective of method used by the primary
authors. Generic inverse variance method of meta-ana-
lyses was used for pooling the data. The assessment of
statistical heterogeneity among trials was done by visual
inspection i.e. the overlap of the confidence intervals
among the studies, and by the Chi square (P-value) of
heterogeneity in the meta-analyses. A low P value (less
than 0.10) or a large chi-squared statistic relative to its
degree of freedom was considered as providing evidence
of heterogeneity. The I2 values were also looked into,
and an I2 greater than 50% was taken to represent sub-
stantial heterogeneity. In situations of substantial hetero-
geneity being present, causes were explored, sub-group
analyses performed and random effects model was used.
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Results of pooled estimates are described as relative risk
(RR) with 95% CI. All meta-analyses were conducted
using the software RevMan version 5 [14]. Data, where
available, were taken for zinc versus placebo/no treat-
ment (control) groups and for zinc plus other micronu-
trient versus other micronutrient, making zinc
supplementation the only difference between the inter-
vention and control groups.
We followed standardized guidelines of Child Health
Epidemiology Reference Group (CHERG) to get esti-
mates of effectiveness of preventive zinc supplementa-
tion in reducing diarrhea and pneumonia specific
mortality [12]. Application of CHERG rules is based on
three components 1) the volume and consistency of the
evidence; 2) the size of the effect, or risk ratio and 3)
the strength of the statistical evidence for an association
between the intervention and outcome. The detailed
description and application of these rules to collective
morbidity and mortality outcomes is provided in the
results and discussion section.
Results
Trial flow
The search on the electronic database and papers from
hand searches yielded 336 titles out of which 18 studies
were included in the present review [15-32] (Figure 1).
Study characteristics
In the included papers, there were two cluster rando-
mized controlled trials [30,31] and the remaining were
individual randomized controlled trials [7,15-29,32,33].
All the trials assessing the effect of zinc supplementa-
tion were conducted in developing countries. There
were 11 studies from Asia [16,18,20-23,25,26,30,31,33],
5 from Africa [17,19,24,27,28] and 3 from Latin Amer-
ica [15,29,32]. Participants in most of the studies were
apparently healthy children. One trial included partici-
pants that had diarrhea in the past 24 hours [7,25],
one included participants with persistent diarrhea [32],
one trial enrolled stunted children [23] and in one
study half of the children were stunted and half were
non-stunted [24]. One study included participants
older than 5 years of age [15]; however, disaggregated
data on children < 5 years of age were available. One
study on morbidity compared weekly supplementation
versus daily supplementation with a placebo group,
both the regimens were included in the analysis as two
data sets (Gupta a , Gupta b) [16]. One study exclu-
sively included HIV-positive children [28], while Lua-
beya et al. included HIV-positive, HIV-negative
children born to HIV-positive mothers and HIV-nega-
tive children born to HIV-negative mothers [19].Addi-
tional File 1 gives the characteristics of included
studies.
The dose of zinc supplementation ranged from 10 to
20 mg with a median of 10 mg. The duration of supple-
mentation ranged from 4.6 to 18 months with a median
of 6 months. Participants in all the studies were supple-
mented with zinc daily except in two studies where
there was a weekly supplementation [16,21]. In three
studies zinc was supplemented with multiple micronu-
trients [22,27,28]. Additional File 2 is the risk of bias
table for all included trials according to the latest
recommendations for the Cochrane Handbook.
Quantitative data synthesis
All cause mortality
Mortality data was reported in ten papers comprising
eight trials [17,19,21,26-28,30,31,34,35]. Of these, one
was cluster RCT [30,34] and seven were individual
RCTs [17,19,21,26,28,31,35]. One trial exclusively
included infants < 12 months of age [21]; the other
seven trials on mortality included children between 1 to
60 months of age [17,19,26,28,30,31,35]. Zinc was given
with vitamin A in three trials [19,27,34], with multiple
micronutrients in one [28] and alone in two trials
[21,26]. But in all these studies, zinc was the only differ-
ence between the intervention and control groups.
Three papers included IFA given in treatment and con-
trol arms [30,31,35].
Some studies were excluded from this analysis. The
study on mortality by Sazawal et al [36] included only
small for gestational age children, and the comparison
was between zinc supplementation and supplementation
with other micronutrients without any zinc, hence it
was not included in the present analysis. The study by
Lira et al. was excluded as supplementation was given
for less than 3 months [37].
Zinc supplementation alone was associated with a sta-
tistically insignificant 9% (RR = 0.91; 95% CI: 0.82, 1.01;
fixed effect model) reduction in all cause mortality in
the intervention group as compared to controls using a
fixed effect model (Figure 2). When studies in which
zinc was given with iron and folic acid (IFA) [30,31,35]
were included in the above analysis, the overall effect on
mortality was reduced to 5% (RR = 0.95; 95% CI: 0.88,
1.02; fixed effect model), though also non-significant
(Figure 2).
Cause specific mortality
Data on cause specific mortality due to diarrhea, pneu-
monia and malaria was provided among five trials con-
sisting of six articles [21,27,28,30,31,34]. In all of these
studies cause of death was usually ascertained through
hospital records and verbal autopsies.
Diarrhea specific mortality was presented in five trials
consisting of six papers [21,27,28,30,31,34]. Analysis
showed a non-significant 18% reduction in deaths due
to diarrheal diseases (RR = 0.82; 95% CI: 0.64, 1.05;
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fixed effect model) among studies using zinc supple-
mentation alone (Figure 3A). The effect decreased to 9%
but remained insignificant (RR = 0.91; 95% CI: 0.76,
1.09) after inclusion of the two studies [30,31] with IFA
supplementation as co-intervention in both the treat-
ment and control arms. According to CHERG rules, we
took the estimate of cause specific mortality reduction
based on zinc supplementation only studies. Using the
modified GRADE criteria, we rated the qualitative
assessment for the above outcomes as low quality [12].
According to CHERG rules for evidence review, low
quality evidence on cause specific mortality cannot be
used as an effectiveness estimate on mortality reduction
for an intervention and other outcomes should be
reviewed [12].
Cause specific mortality data due to pneumonia were
included in five trials presented in six papers
[21,27,28,30,31,34]. Analysis of zinc supplementation
only trials showed a 15% non-significant reduction in
pneumonia specific mortality (RR = 0.85; 95%: CI 0.65,
1.11) in zinc recipients compared to controls. Further
inclusion of studies with IFA [30,31] showed a 20%
reduction in pneumonia specific mortality which did
reach statistical significance (RR = 0.80; 95% CI: 0.67,
0.96) (Figure 3B). In one study [21] there were no
deaths due to pneumonia in the zinc arm and 10 deaths
in the control arm; the results remained consistent with
reduction in mortality due to pneumonia after exclusion
of the mentioned study. According to CHERG rules for
evidence review, the level of evidence in support of zinc
supplementation affecting pneumonia mortality in under
5 children was of low quality, as the overall results from
trials of zinc supplementation alone on pneumonia mor-
tality were statistically non-significant.
Malaria specific mortality data were provided in one
large trial from Africa with zinc supplementation com-
pared to placebo [27]. This was a large randomized con-
trolled trial, with an overall high grade given to the
individual study. There were 272 deaths in the zinc sup-
plementation arm and 302 deaths in the control arm,
and a 10% non-significant reduction in malaria specific
mortality was observed (RR = 0.90; 95% CI: 0.77, 1.06).
Numberofstudiesidentified
(n=336)
Recordsexcluded
(n=296)
FullͲtextarticlesassessedfor
eligibility(n=40)
Recordsscreened
(n=336)
FullͲtextarticlesexcluded
(n=22)
AllͲcause
mortality
n=8  
Pneumonia
specificmorbidity
n=6
Pneumonia
specificmortality
n=5 
Diarrheaspecific
morbidity
n=14 
Diarrheaspecific
mortality
n=5 
Studiesincludedinthe
review
(n=18)
Figure 1 Flow diagram showing identification of studies.
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As the above data was provided from a single study the
quality of overall evidence was rated as low.
Cause-specific morbidity impact estimation
Morbidity data on incidence of diarrhea were presented in
14 trials that met our eligibility criteria [15-25,28,29,34].
Generally, the age of the included participants ranged
from newborn healthy children aged 5 years of age. In the
study by Richard et al. children up to 15 years of age were
included, however disaggregated data were available for
children < 5 years of age [15]. In the study by Long et al.
there were four groups: zinc, vitamin A plus zinc, vitamin
A and placebo [29]. We were unable to compute risk ratio
for zinc plus vitamin A versus vitamin A group and so
used the risk ratio for zinc versus placebo only. Studies
where zinc was given with IFA were not considered for
any of the morbidity analyses.
The pooled analysis showed a significant reduction of
13% (RR = 0.87; 95% CI: 0.81, 0.94); random effects
model) on the incidence of diarrheal episodes in zinc
supplemented group as compared to control group
(Figure 4). Hospitalization due to diarrheal episodes was
reported by one study [19] with less than 50 events and,
therefore, could not be included in the review as per
CHERG rules [12].
The effect of zinc supplementation on pneumonia
morbidity (definition rapid respiratory rate with or with-
out other signs of pneumonia) was estimated from six
RCTs [7,19,21,28,32,33]. Three RCTs [15,18,22] and
data from one cluster RCTs [34] were not included in
this morbidity analysis because the diagnostic signs used
did not clearly identify pneumonia or depended upon
self reporting by the patient. The analysis showed a 19%
reduction in pneumonia morbidity in children who
received zinc as compared to control (RR = 0.81; 95%
CI: 0.73, 0.90) (Figure 5).
Four studies [9,15,17,26] evaluated the effect of zinc
supplementation on incidence of uncomplicated malarial
episodes with parasitemia. The pooled estimate of effect
was an 8% (RR 0.92; 95% CI 0.82, 1.04) reduction in
occurrence of malarial episodes in the zinc group as
compared to control.
Discussion
The benefits of preventive zinc supplementation are well
established on morbidity related to infections, however;
there has been no attempt to quantify the effect of preven-
tive zinc supplementation on cause specific mortality in
children which is a new aspect in our review compared to
Study or Subgroup
5.2.1 Zinc alone versus control
Bobat
Brooks
Luabeya
Muller
Sazawal 2007
Shankar
Tielsch 2007
Subtotal (95% CI)
Heterogeneity: Chi² = 12.08, df = 6 (P = 0.06); I² = 50%
Test for overall effect: Z = 1.79 (P = 0.07)
5.2.2 Zinc plus IFA versus IFA
Bhandari 2007
Sazawal 2006
Tielsch 2006
Subtotal (95% CI)
Heterogeneity: Chi² = 0.23, df = 2 (P = 0.89); I² = 0%
Test for overall effect: Z = 0.12 (P = 0.91)
Total (95% CI)
Heterogeneity: Chi² = 13.51, df = 9 (P = 0.14); I² = 33%
Test for overall effect: Z = 1.43 (P = 0.15)
Test for subgroup differences: Chi² = 1.19, df = 1 (P = 0.27), I² = 16.3%
Weight
0.3%
0.3%
0.3%
0.6%
30.2%
0.1%
24.9%
56.6%
22.8%
11.9%
8.7%
43.4%
100.0%
IV, Fixed, 95% CI
0.31 [0.07, 1.37]
0.17 [0.04, 0.72]
2.00 [0.51, 7.84]
0.41 [0.15, 1.12]
0.93 [0.81, 1.07]
3.04 [0.32, 28.88]
0.92 [0.79, 1.07]
0.91 [0.82, 1.01]
1.02 [0.87, 1.20]
0.96 [0.77, 1.20]
0.97 [0.75, 1.25]
0.99 [0.88, 1.11]
0.95 [0.88, 1.02]
Risk Ratio Risk Ratio
IV, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours experimental Favours control
Figure 2 Effect of zinc supplementation on all-cause mortality in children less than five years of age.
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previous reviews on the subject. In their review of preven-
tive zinc supplementation, Brown et al. [38] pooled data
on children across all age groups (infants, preschoolers
and older prepubertal children) and reported a 6% non-
significant reduction in all-cause mortality. They also indi-
cated that the mortality reduction with zinc supplementa-
tion versus placebo was only significant (18%) among
children older than 12 months of age, with a tendency
A)
Study or Subgroup
5.4.1 Zinc alone vs. control
Bobat
Brooks
Sazawal 2007
Tielsch 2007
Subtotal (95% CI)
Heterogeneity: Chi² = 1.53, df = 3 (P = 0.68); I² = 0%
Test for overall effect: Z = 1.55 (P = 0.12)
5.4.2 Zinc plus IFA vs. IFA
Bhandari 2007
Tielsch 2006
Subtotal (95% CI)
Heterogeneity: Chi² = 0.04, df = 1 (P = 0.84); I² = 0%
Test for overall effect: Z = 0.20 (P = 0.84)
Total (95% CI)
Heterogeneity: Chi² = 3.00, df = 5 (P = 0.70); I² = 0%
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Chi² = 1.43, df = 1 (P = 0.23), I² = 29.9%
Weight
0.3%
0.6%
7.1%
46.4%
54.5%
29.3%
16.2%
45.5%
100.0%
IV, Fixed, 95% CI
0.22 [0.01, 4.84]
2.39 [0.22, 25.97]
0.89 [0.45, 1.76]
0.81 [0.62, 1.06]
0.82 [0.64, 1.05]
1.05 [0.75, 1.47]
0.99 [0.63, 1.56]
1.03 [0.78, 1.35]
0.91 [0.76, 1.09]
Risk Ratio Risk Ratio
IV, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours experimental Favours control
B)
Study or Subgroup
5.5.1 Zinc alone vs. control
Bobat
Brooks
Sazawal 2007
Tielsch 2007
Subtotal (95% CI)
Heterogeneity: Chi² = 4.88, df = 3 (P = 0.18); I² = 39%
Test for overall effect: Z = 1.21 (P = 0.23)
5.5.2 Zinc plus IFA vs. IFA
Bhandari 2007
Tielsch 2006
Subtotal (95% CI)
Heterogeneity: Chi² = 0.47, df = 1 (P = 0.49); I² = 0%
Test for overall effect: Z = 2.09 (P = 0.04)
Total (95% CI)
Heterogeneity: Chi² = 5.68, df = 5 (P = 0.34); I² = 12%
Test for overall effect: Z = 2.35 (P = 0.02)
Test for subgroup differences: Chi² = 0.32, df = 1 (P = 0.57), I² = 0%
Weight
1.5%
0.4%
10.5%
34.9%
47.4%
41.9%
10.7%
52.6%
100.0%
IV, Fixed, 95% CI
0.36 [0.08, 1.62]
0.06 [0.00, 0.97]
0.88 [0.50, 1.55]
0.90 [0.66, 1.23]
0.85 [0.65, 1.11]
0.73 [0.55, 0.97]
0.91 [0.52, 1.59]
0.76 [0.59, 0.98]
0.80 [0.67, 0.96]
Risk Ratio Risk Ratio
IV, Fixed, 95% CI
0.2 0.5 1 2 5
Favours experimental Favours control
Figure 3 Forest plot for the effect of zinc supplementation on cause-specific mortality in children less than five years of age: A) due to diarrheal
diseases B) due to pneumonia.
Yakoob et al. BMC Public Health 2011, 11(Suppl 3):S23
http://www.biomedcentral.com/1471-2458/11/S3/S23
Page 6 of 10
towards increased mortality in children less than 12
months. We, on the other hand, have evaluated the effect
of zinc on all cause mortality, cause specific mortality and
cause specific morbidity in children less than 5 years of
age from developing countries receiving preventive zinc
supplementation for a minimum period of three months.
The studies of shorter duration were excluded as preven-
tive zinc supplementation may require longer duration of
supplementation to replete the body stores compared to
that of therapeutic supplementation for diarrhea/pneumo-
nia where two weekly doses are enough to fulfill the acute
deficiency. Our results are similar to those reported by
Brown et al., even though we restricted to the studies with
children less than five years of age. Our 9% reduction in
all-cause mortality was also non-significant. In our review,
for the LiST model, estimates are presented from zinc
only studies compared with placebo/no treatment, which
may not be applicable to countries where there are on-
going national supplementation programs of iron-folate,
for example, India.
Table 1 gives grade quality of overall evidence. Zinc
supplementation alone was associated with non-signifi-
cant reductions in mortality due to diarrhea, pneumonia
and malaria. Table 2 summarizes the application of
Study or Subgroup
Baqui
Bhandari 2002
Bobat
Brooks
Gupta 2003a
Gupta 2003b
Long 2006a
Luabeya
Muller
Ninh
Osendarp
Richard 2006a
Sazawal 1997
Tielsch 2007
Umeta
Total (95% CI)
Heterogeneity: Tau² = 0.01; Chi² = 66.47, df = 14 (P < 0.00001); I² = 79%
Test for overall effect: Z = 3.62 (P = 0.0003)
Weight
8.7%
10.1%
2.6%
10.3%
1.7%
1.7%
7.9%
8.9%
9.4%
4.5%
7.1%
4.8%
8.8%
10.5%
3.1%
100.0%
IV, Random, 95% CI
0.98 [0.87, 1.10]
0.88 [0.82, 0.94]
0.51 [0.34, 0.77]
0.94 [0.88, 1.00]
0.41 [0.24, 0.70]
0.41 [0.24, 0.70]
1.13 [0.98, 1.30]
0.94 [0.84, 1.05]
0.87 [0.79, 0.96]
0.71 [0.54, 0.93]
1.10 [0.93, 1.30]
0.70 [0.54, 0.91]
0.92 [0.82, 1.03]
0.96 [0.91, 1.01]
0.46 [0.32, 0.66]
0.87 [0.81, 0.94]
Risk Ratio Risk Ratio
IV, Random, 95% CI
0.01 0.1 1 10 100
Favours experimental Favours control
Figure 4 Forest plot for the effect of zinc supplementation on diarrhea morbidity (incidence).
Study or Subgroup
Bhandari 2002
Bobat
Brooks
Luabeya
Penny
Sazawal 1998a
Total (95% CI)
Heterogeneity: Chi² = 4.70, df = 5 (P = 0.45); I² = 0%
Test for overall effect: Z = 4.03 (P < 0.0001)
Weight
14.6%
11.1%
64.7%
3.0%
2.6%
4.1%
100.0%
IV, Fixed, 95% CI
0.76 [0.58, 1.00]
0.75 [0.55, 1.02]
0.83 [0.73, 0.94]
1.18 [0.65, 2.14]
0.99 [0.52, 1.88]
0.55 [0.33, 0.92]
0.81 [0.73, 0.90]
Risk Ratio Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours experimental Favours control
Figure 5 Forest plot for the effect of zinc supplementation on pneumonia morbidity (incidence).
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CHERG rules to estimate effects for diarrhea and pneu-
monia specific mortality [12]. Zinc supplementation was
associated with an 18% (RR = 0.82; 95% CI: 0.64, 1.05)
reduction in deaths due to diarrheal diseases in under 5
children from developing countries. However, as the
above values were statistically non-significant the evi-
dence on cause specific mortality was labeled as low
quality. In looking at severe morbidity estimates as sur-
rogate measures, such as hospitalization due to diarrhea,
this information was only available from one study with
Table 1 Quality assessment of overall evidence for effect of zinc supplementation (alone) in reducing morbidity and
mortality in children > 5 years of age in developing countries
No of
studies
(ref )
Study
Design
Limitations Consistency Generalizability to
Population of
Interest
Generalizability to intervention of
interest
Relative
Risk
(95% CI)
Outcome: All-cause mortality: Quality of evidence: Low
7 RCTs Sequence generation and
allocation concealment was
unclear in few of the included
studies
I2= 50% Yes (all studies were
conducted in
developing
countries)
The median dose of supplementation was
10 mg/day and median duration of
supplementation was for 6 months.
0.91
(0.82-
1.01)
Outcome: Diarrhea specific mortality: Quality of evidence: Low
4 RCTs Allocation concealment was
unclear in two of the included
studies
I2=0% Yes (all studies were
conducted in
developing
countries)
The median dose of supplementation was
10 mg/day and median duration of
supplementation was for 6 months.
0.82
(0.64-
1.05)
Outcome: Diarrhea specific morbidity: Quality of evidence: Moderate
14 RCTs Sequence generation and
allocation concealment was
unclear in few of the included
studies
I2=79% Yes (all studies were
conducted in
developing
countries)
The median dose of supplementation was
10 mg/day and median duration of
supplementation was for 6 months.
0.87
(0.81-
0.94)
Outcome: Pneumonia specific mortality: Quality of evidence: Low
4 RCTs Allocation concealment was
unclear in two of the included
studies
I2= 39% Yes (all studies were
conducted in
developing
countries)
The median dose of supplementation was
10 mg/day and median duration of
supplementation was for 6 months.
0.85
(0.65-
1.11)
Outcome: Pneumonia specific morbidity: Quality of evidence: Moderate
6 RCTs Sequence generation and
allocation concealment was
unclear in few of the included
studies
I2=0% Yes (all studies were
conducted in
developing
countries)
The median dose of supplementation was
10 mg/day and median duration of
supplementation was for 6 months.
0.81
(0.73-
0.90)
Outcome: Malaria specific mortality: Quality of evidence: Low
1 RCT None NA Study conducted in
Zanzibar
Dose of supplementation was 10 mg/dl for
children > 1 year and 5mg/day for children
< 1 years.
0.90
(0.77-
1.06)
Outcome: Malaria specific morbidity: Quality of evidence: Low
4 RCTs Allocation concealment was
unclear in two of the included
studies
I2=0% Yes (all studies were
conducted in
developing
countries)
The median dose of supplementation was
10 mg/day and median duration of
supplementation was for 6 months.
0.92
(0.82-
1.04)
Table 2 Application of standardized rules for choice of final outcome to estimate effect of zinc supplementation on
mortality due to diarrhea, pneumonia and malaria in children less than 5 years of age
Outcome measure Studies Relative risk reduction Application of standard rules
Cause specific mortality (diarrhea) 4 18% reduction;
RR = 0.82 (0.64, 1.05) (Low quality of evidence)
Incidence of diarrhea 14 13% reduction;
RR = 0.87 (0.81, 0.94)
Rule 6 is applied
(Moderate quality of evidence)
(Effect Recommended for LiST)
Cause specific mortality (pneumonia)
(Zinc only studies)
4 15% reduction;
RR = 0.85 (0.65, 1.11)
Rule 6 applied
(Low quality of evidence)
(Effect Recommended for LiST)
Pneumonia morbidity 6 19% reduction;
RR = 0.81 (0.73, 0.90)
Rule 6 applied
(Moderate quality of evidence)
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an overall event rate of less than 50 [12]. As per
CHERG rules, we, therefore, considered the impact of
zinc supplementation on diarrheal incidence for a point
estimate of impact on diarrhea mortality as the evidence
was of moderate quality[12]. With the above outcomes
we took the most conservative effect between the avail-
able low quality evidence on diarrheal specific mortality
and moderate quality evidence on mild morbidity. Using
this sequential application of CHERG rules to the above
outcomes, the observed 13% reduction (RR = 0.87; 95%
CI: 0.81, 0.94) in diarrhea incidence was taken as an
effect estimate for the protective effect of zinc supple-
mentation on diarrheal disease mortality and recom-
mended for inclusion in LiST tool [12].
A similar effect of zinc was shown for pneumonia. Zinc
only supplementation studies revealed a pooled effect size
of 15% (RR = 0.85; 95% CI: 0.65, 1.11) reduction on pneu-
monia mortality but the overall quality of evidence was
rated as low. We applied CHERG rules on studies with
information on pneumonia morbidity outcomes where the
overall evidence quality was rated as moderate. Applying
CHERG rules we used the most conservative impact esti-
mate from available outcomes i.e. 15% as our pooled sur-
rogate effect size for mortality[12]. Deaths due to malaria
were included only in one study which reported a 10%
(RR = 0.90; 95% CI: 0.77, 1.06) reduction in malarial mor-
tality (low quality of evidence). In the present review there
was insufficient evidence of a protective effect of zinc sup-
plementation on malarial mortality or morbidity. There-
fore no estimates can be given for effect of zinc
supplementation on reduction of deaths due to malaria for
inclusion in the LiST tool.
Our review did not give any conclusive evidence about
any possible positive or negative interaction between zinc
and iron whereby iron decreases the absorption or bioa-
vailability of zinc. With the inclusion of IFA studies for
all-cause mortality, the results remained non-significant.
For diarrhea-specific mortality, with inclusion of IFA stu-
dies, the impact estimate of reduction decreased from 18%
to 9% but the results in both the situations were statisti-
cally non-significant. For pneumonia-specific mortality,
however, a beneficial effect was seen as the impact of all
the studies came out to be significant (RR = 0.80; 95% CI:
0.67, 0.96) compared to a 15% non-significant reduction
with zinc alone studies (RR = 0.85; 95% CI: 0.65, 1.11).
To conclude, the application of CHERG rules to avail-
able evidence on diarrhea and pneumonia for providing
effect estimates of protective effect for zinc supplemen-
tation in children for a minimum period of 3 months
indicates 13% (RR = 0.87; 95% CI: 0.81, 0.94) reduction
in mortality due to diarrheal diseases and 15% (RR =
0.85; 95% CI: 0.65, 1.11) reduction in pneumonia speci-
fic mortality. Our analysis supports inclusion of preven-
tive zinc supplementation in public health programs to
improve child health and survival and the suggested
point estimates provide a suitable starting point for
inclusion within the LiST tool and further program eva-
luation in effectiveness settings.
Additional material
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